1004534-79-5Relevant academic research and scientific papers
NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
-
Paragraph 0135, (2019/01/05)
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
2-(2′-((Dimethylamino)methyl)-4′-(fluoroalkoxy)-phenylthio) benzenamine derivatives as serotonin transporter imaging agents
Parhi, Ajit K.,Wang, Julie L.,Oya, Shunichi,Choi, Seok-Rye,Kung, Mei-Ping,Kung, Hank F.
, p. 6673 - 6684 (2008/09/17)
A novel series of ligands with substitutions at the 5-position on phenyl ring A and at the 4′-position on phenyl ring B of 2-(2′- ((dimethylamino)methyl)-4′-(fluoroalkoxy)phenylthio)benzenamine (4′-2-fluoroethoxy derivatives 28-31 and 4′-3-fluoropropoxy d
